RxDoctor Payments Data

Bradley Luttrell, MD

Ophthalmology · Oak Ridge, TNNPI 1508850298

Payments from drug & device makers

$3,651in general payments, 2019–2025

Across 152 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$683
  • Alcon$618
  • Tarsus Pharmaceuticals, Inc.$399
  • AbbVie$352
  • Ivantis, Inc$205
  • Biotissue Holdings Inc.$194
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,651 in reported general payments places this provider in the 70th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$284,518
Medicare patients
765
Services billed
3,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$70,247
XiidraLifitegrast44$54,413
Cyclosporine26$22,124
LumiganBimatoprost34$14,691
Prednisolone Acetate166$6,031
CombiganBrimonidine Tartrate/Timolol18$4,660
Travoprost12$4,115
Latanoprost324$3,990
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,884
Brimonidine Tartrate52$1,493
Timolol Maleate94$1,156
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha79$1,010
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$192
Doxycycline Hyclate13$177
ErythromycinErythromycin Base11$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$352$89,598121 claims
Bausch & Lomb Americas Inc.Xiidra$38$54,41344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →